Literature DB >> 25077106

Mortality in a large community-based cohort of inner-city residents in Vancouver, Canada.

Gregory D Deans1, Jesse D Raffa2, Calvin Lai3, Benedikt Fischer4, Mel Krajden5, Janaki Amin6, Scott R Walter7, Gregory J Dore6, Jason Grebely6, Mark W Tyndall8.   

Abstract

BACKGROUND: The Downtown Eastside is a robust and densely populated neighbourhood in Vancouver, Canada, that is characterized by low-income housing and drug use and a high prevalence of HIV infection. We evaluated mortality and excess mortality among the broader community of individuals living in this neighbourhood.
METHODS: The Community Health and Safety Evaluation is a community-based study of inner-city residents in the Downtown Eastside who were recruited in 2003 and 2004. Participants' data were linked with data in provincial virology and mortality databases retrospectively and prospectively for the period 1991-2009. Mortality and standardized mortality ratios (SMRs) were calculated for the period 2003-2009 to compare death rates in the study population with rates in the population of Vancouver.
RESULTS: Among 2913 participants, 374 deaths occurred, for an all-cause mortality of 223 per 10 000 person-years (95% confidence interval [CI] 201-247 per 10 000 person-years). Compared with the population of Vancouver, significant excess mortality was observed in the study population (SMR 7.1, 95% CI 6.4-7.9). Excess mortality was higher among women (SMR 15.4, 95% CI 12.8-18.5) than among men (SMR 5.8, 95% CI 5.1-6.6). Although crude mortality increased with age, excess mortality was greatest among participants less than 35 years old (SMR 13.2, 95% CI 9.4-18.5) and those 35-39 years old (SMR 13.3, 95% CI 10.3-17.1). Excess risk was also elevated among participants with hepatitis C virus (HCV), HIV and HCV/HIV infection, with SMRs of 5.9 (95% CI 4.9-7.1), 19.2 (95% CI 12.8-28.9) and 23.0 (95% CI 19.3-27.4), respectively.
INTERPRETATION: Our study showed high mortality in this inner-city population, particularly when compared with the general population of Vancouver. Excess mortality was highest among women, younger participants and those infected with either HCV or HIV or both.

Entities:  

Year:  2013        PMID: 25077106      PMCID: PMC3985976          DOI: 10.9778/cmajo.20130002

Source DB:  PubMed          Journal:  CMAJ Open        ISSN: 2291-0026


  28 in total

Review 1.  Review of sampling hard-to-reach and hidden populations for HIV surveillance.

Authors:  Robert Magnani; Keith Sabin; Tobi Saidel; Douglas Heckathorn
Journal:  AIDS       Date:  2005-05       Impact factor: 4.177

2.  The increasing mortality burden of liver disease among opioid-dependent people: cohort study.

Authors:  Amy Gibson; Deborah Randall; Louisa Degenhardt
Journal:  Addiction       Date:  2011-10-17       Impact factor: 6.526

3.  Syringe sharing and HIV incidence among injection drug users and increased access to sterile syringes.

Authors:  Thomas Kerr; Will Small; Chris Buchner; Ruth Zhang; Kathy Li; Julio Montaner; Evan Wood
Journal:  Am J Public Health       Date:  2010-06-17       Impact factor: 9.308

4.  Impact of hepatitis C virus infection on all-cause and liver-related mortality in a large community-based cohort of inner city residents.

Authors:  J Grebely; J D Raffa; C Lai; T Kerr; B Fischer; M Krajden; G J Dore; M W Tyndall
Journal:  J Viral Hepat       Date:  2011-01       Impact factor: 3.728

5.  Community-acquired pneumonia in a cohort of former injection drug users with and without human immunodeficiency virus infection: incidence, etiologies, and clinical aspects.

Authors:  A Boschini; C Smacchia; M Di Fine; A Schiesari; P Ballarini; M Arlotti; C Gabrielli; G Castellani; M Genova; P Pantani; A C Lepri; G Rezza
Journal:  Clin Infect Dis       Date:  1996-07       Impact factor: 9.079

6.  Changing patterns in causes of death in a cohort of injecting drug users, 1980-2001.

Authors:  Lorraine Copeland; John Budd; J Roy Robertson; Rob A Elton
Journal:  Arch Intern Med       Date:  2004-06-14

7.  The shifting pattern of cause-specific mortality in a cohort of human immunodeficiency virus-infected and non-infected injecting drug users.

Authors:  Inmaculada Ferreros; Blanca Lumbreras; Isabel Hurtado; Santiago Pérez-Hoyos; Ildefonso Hernández-Aguado
Journal:  Addiction       Date:  2008-04       Impact factor: 6.526

8.  Risk factors for elevated HIV incidence among Aboriginal injection drug users in Vancouver.

Authors:  Kevin J P Craib; Patricia M Spittal; Evan Wood; Nancy Laliberte; Robert S Hogg; Kathy Li; Katherine Heath; Mark W Tyndall; Michael V O'Shaughnessy; Martin T Schechter
Journal:  CMAJ       Date:  2003-01-07       Impact factor: 8.262

9.  Mortality among injection drug users in Chennai, India (2005-2008).

Authors:  Sunil S Solomon; David D Celentano; Aylur K Srikrishnan; Canjeevaram K Vasudevan; Santhanam Anand; Muniratnam S Kumar; Suniti Solomon; Gregory M Lucas; Shruti H Mehta
Journal:  AIDS       Date:  2009-05-15       Impact factor: 4.177

10.  Factors associated with premature mortality among young injection drug users in Vancouver.

Authors:  Cari L Miller; Thomas Kerr; Steffanie A Strathdee; Kathy Li; Evan Wood
Journal:  Harm Reduct J       Date:  2007-01-04
View more
  7 in total

1.  Misplaced advocacy: What does better hepatitis C treatment really mean?

Authors:  Mark Tyndall
Journal:  CMAJ       Date:  2015-08-04       Impact factor: 8.262

2.  The Hotel Study-Clinical and Health Service Effectiveness in a Cohort of Homeless or Marginally Housed Persons.

Authors:  William G Honer; Alejandro Cervantes-Larios; Andrea A Jones; Fidel Vila-Rodriguez; Julio S Montaner; Howard Tran; Jimmy Nham; William J Panenka; Donna J Lang; Allen E Thornton; Talia Vertinsky; Alasdair M Barr; Ric M Procyshyn; Geoffrey N Smith; Tari Buchanan; Mel Krajden; Michael Krausz; G William MacEwan; Kristina M Gicas; Olga Leonova; Verena Langheimer; Alexander Rauscher; Krista Schultz
Journal:  Can J Psychiatry       Date:  2017-02-15       Impact factor: 4.356

3.  Elimination of HCV as a public health concern among people who inject drugs by 2030 - What will it take to get there?

Authors:  Jason Grebely; Gregory J Dore; Sébastien Morin; Jürgen K Rockstroh; Marina B Klein
Journal:  J Int AIDS Soc       Date:  2017-07-28       Impact factor: 5.396

4.  Trends in cause-specific mortality in HIV-hepatitis C coinfection following hepatitis C treatment scale-up.

Authors:  Nadine Kronfli; Sahir R Bhatnagar; Mark W Hull; Erica E M Moodie; Joseph Cox; Sharon Walmsley; John Gill; Curtis Cooper; Valérie Martel-Laferrière; Neora Pick; Marina B Klein
Journal:  AIDS       Date:  2019-05-01       Impact factor: 4.177

5.  Are Interferon-Free Direct-Acting Antivirals for the Treatment of HCV Enough to Control the Epidemic among People Who Inject Drugs?

Authors:  Viviane D Lima; Ignacio Rozada; Jason Grebely; Mark Hull; Lillian Lourenco; Bohdan Nosyk; Mel Krajden; Eric Yoshida; Evan Wood; Julio S G Montaner
Journal:  PLoS One       Date:  2015-12-03       Impact factor: 3.240

6.  Impact of individualized care on readmissions after a hospitalization for acute exacerbation of COPD.

Authors:  Simon L Adamson; Jane Burns; Pat G Camp; Don D Sin; Stephan F van Eeden
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2016-01-05

7.  Social and structural factors associated with substance use within the support network of adults living in precarious housing in a socially marginalized neighborhood of Vancouver, Canada.

Authors:  Verena Knerich; Andrea A Jones; Sam Seyedin; Christopher Siu; Louie Dinh; Sara Mostafavi; Alasdair M Barr; William J Panenka; Allen E Thornton; William G Honer; Alexander R Rutherford
Journal:  PLoS One       Date:  2019-09-23       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.